Prof. Ette is the president/chief scientific officer of Anoixis Corporation, a fellow of the American College of Clinical Pharmacology, the American College of Clinical Pharmacy (ACCP), the American Association of Pharmaceutical Sciences, and the Nigerian Academy of Pharmacy. He is a scientific and clinical advisory board member of Cellanyx, Inc., and Hospital for Humanity, respectively, and the University of Namibia's honorary professor of clinical pharmacology/pharmacometrics.
Prof. Ette is the 2025 recipient (the first African recipient) of the American Society of Clinical Pharmacology and Therapeutics’ Sheiner-Beal Pharmacometrics Award. The Sheiner-Beal Pharmacometrics Award recognizes outstanding achievements of individuals at the forefront of research or leadership in pharmacometrics and/or the application of pharmacometric concepts and techniques to enhance research, development, regulatory evaluation, and/or the utilization of therapeutic products. He was the 2006 recipient (the first African recipient) of ACCP’s Therapeutic Frontier Lecture Award for outstanding contributions to pharmacotherapy and the 1999 recipient (the first African recipient) of ACCP’s Russell Miller Award for sustained contributions to the pharmacotherapy literature.
Prof. Ette was the first recipient of the Center for Drug Evaluation and Research, Food and Drug Administration (FDA)’s Excellence in Review Science Award in 1996 for his outstanding research, which advanced drug development and evaluation science through pharmacometrics. His findings served as the basis for the 1999 FDA's unique Guidance for Industry: Population Pharmacokinetics, which revolutionized drug development and evaluation worldwide. He is the first black African pharamcometician/professor of pharmacometrics; senior editor of the worldwide classic pharmacometrics reference textbook, Pharmacometrics: The Science of Quantitative Pharmacology, biomedical journals’ editorial board member, and supervisor of many Ph.D. theses in America and Africa.
He is an innovative drug developer and the co-inventor of the first-ever patent for shortening hepatitis C treatment duration from 48 to 24 weeks with telaprevir, making treatment durations below 24 weeks possible.
